STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #469 by analyst upside · 2026-06-27
FBRX
Forte Biosciences, Inc.
Healthcare · Market Cap $431M · P/E 0x
ANALYST PRICE TARGET
+203.1%
implied upside to consensus target
Current Price $21.03
Consensus Target $63.75
Bull Target $75.0
Bear Target $54.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $9.1
52-Week High $35.8
YTD Return -10.9%
FUNDAMENTALS
Market Cap $431M
P/E Ratio (TTM) N/A
Forward P/E -5.1x
EPS (TTM) $-5.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $9.1
52-Week High $35.8
Current Price $21.03
Bear Target $54.0
Bull Target $75.0
● Now $21.03 ● Target $63.75
TRADING DATA
Avg Volume 299K
YTD Return -10.9%
Analyst Count 4
Consensus Buy
Upside to Target +203.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Forte Biosciences, Inc. (FBRX) is currently trading at $21.03 with a Wall Street consensus price target of $63.75, implying potential upside of 203.1% over the next 12 months. 4 analysts currently cover FBRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $75.0, while the most cautious has a target of $54.0.

FBRX operates in the Healthcare sector with a market capitalisation of $431M. The stock is down 10.9% year-to-date and is currently trading near the lower end of its 52-week range of $9.1 – $35.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for FBRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group ● Initiated
Outperform 2025-11-25 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-11-17 33% win rate (6 calls)
Guggenheim ● Initiated
Buy 2025-08-18 62% win rate (8 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-08-15 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-06-24 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-04-01 33% win rate (6 calls)
TD Cowen ● Initiated
Buy 2025-01-21 Building track record
Chardan Capital — Reiterated
Buy → Buy 2024-12-04 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
12/30
Consensus clarity
10/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →